Pd source model, and ͑3͒ the radiation oncologist in collaboration with the medical physicist should decide which clinical experience they wish to duplicate; the one prior to 1997 or the one from 1997 to 1999. If the intent is to duplicate the experience prior to 1997, which is backed by the long-term follow-up and published outcome studies, then the prior prescriptions of 115 Gy should be replaced by 124 Gy to duplicate that experience.
I. INTRODUCTION
Brachytherapy sources containing 103 Pd are widely used for permanent implants of the prostate and other anatomic sites. Due to evolution of new source strength standards and improvements in dosimetry of low-energy brachytherapy sources, current dose estimates around 103 Pd brachytherapy sources may differ by as much as 17% from doses as evaluated by standard dosimetry protocols. This has resulted in time-dependent discrepancies between prescribed and administered doses conceptually similar to 125 I brachytherapy. 1 The purpose of this communication is to review these 103 Pd source dosimetry developments and to present correction factors defining the relationship between prescribed and administered dose and dose as a function of time period within the history of 103 Pd brachytherapy. The term ''administered dose'' is understood to denote the dose calculated using 1999-era dosimetry parameters and source-strength standards. The goal is to assist radiation oncologists in selecting the prescribed dose that best realizes their clinical intent. This document represents the guidance of the American Association of Physicists in Medicine ͑AAPM͒ on this issue and was prepared by AAPM's Low Energy Interstitial Brachytherapy Dosimetry Subcommittee ͑Chair, J. Williamson͒ and approved by its Radiation Therapy Committee and Science Council.
The first 103 Pd interstitial brachytherapy source was the Model 200 ͑TheraSeed®͒ source, introduced by Theragenics Corporation in 1987, which remained the sole 103 Pd source on the market until 1999. Since no primary standard for airkerma strength (S K ) was available until 1999, apparent activity (A app ), as measured by an in-house assay method developed and maintained by the vendor, was used to specify Model 200 source strength. Using a NaI ͑Tl͒ photon spectrometer, A app was measured by intercomparing the transverse-axis photon fluence rate of Model 200 seeds with that of a 109 Cd source standard bearing an activity calibration traceable to the National Institute of Standards and Technology ͑NIST͒ primary activity standard. Given this operational definition, no a priori relationship between A app and more fundamental quantities such as activity, air kerma, or airkerma strength (S K ) can be assumed. Only recently was S K per unit A app rigorously measured.
Most clinics have used the dose distribution recommended by Task Group 43 ͑TG 43͒ 2 for dosimetric treatment planning and evaluation of Model 200 103 Pd seed implants. The TG-43 dose-rate constants, radial dose functions, anisotropy functions, and anisotropy factors were derived from the TLD dose-rate measurements about the Model 200 source reported by Meigooni 3 and Chiu-Tsao. 4 To estimate the dose-rate constant, dose-rate measurements at 1 cm were normalized to nominal S K inferred from the A app value provided by the vendor at that time ͑1988 and 1989͒. Although this approach does not utilize a well-defined physical quantity for source strength specification, it is a consistent system. As long as Theragenics' A app calibration assays are reproducible from batch-to-batch and remain constant over time, the accuracy of computed 103 Pd dose distributions is limited only by the accuracy of the dose-rate measurements underlying the TG-43 recommendations.
Several developments have raised questions regarding the accuracy and constancy of the current 103 Pd dose-calculation system described above. These include the following ͑1͒ The development of an air-kerma strength primary standard at NIST applicable to Model 200 seeds as well as other low-energy photon-emitting interstitial brachytherapy sources. This standard is based upon the wide angle free-air chamber ͑WAFAC͒ developed by Loevinger. Cd calibration standard. 9 After further evaluation of their calibration constancy data, Theragenics stated that, relative to the 1988-1990 standard, A app values were essentially constant until 21 September 1997, at which time the reported source strengths were reduced by 8%.
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͑3͒
The availability of several new 103 Pd interstitial products with calibrations traceable to the NIST WAFAC standard along with dosimetry parameters 11, 12 normalized to this standard. The availability of different 103 Pd products based upon different and potentially incompatible dosimetry systems has created a situation where it is unclear which prescribed dose should be selected in order to reproduce previous clinical experience. ͑4͒ Recent experimental 13 The problem of relating prescribed to administered dose is common to all types of 103 Pd interstitial sources regardless of manufacturer. Because the entire evaluated and published clinical experience of 103 Pd brachytherapy is based upon patients treated with the Model 200 source, a detailed analysis of the Model 200 source dosimetry parameters and Theragenics' calibration practice is necessary to determine the relationship between prescribed and administered dose as a function of time. Only by reference to the clinical experience and prescribed-to-administered dose ratios associated with this product can radiation oncologists rationally select a prescribed dose for implants using 103 Pd seeds manufactured by others.
II. METHOD AND MATERIALS
A. Manufacturer calibration techniques for the Model 200 source
Prior to the implementation of NIST's WAFAC standard in 1999, a primary S K standard was not available for 103 Pd or any other low-energy interstitial seed with the exceptions of the 3M ͑now Nycomed Amersham͒ 125 I seeds, models 6701, 6702, and 6711. 15 Consequently, in the 1980s, Theragenics developed a method of measuring apparent activity using a NaI ͑Tl͒ scintillation detector. A 103 Pd seed is calibrated through intercomparison to a source with a similar photon spectrum, which has a NIST-traceable contained activity calibration. 103 Pd emits photons with energies of 20.1 keV ͑64.7%͒ and 23.0 keV ͑12.3%͒ with a half-life of 16.99 days. 16 A suitable calibration standard is 109 Cd, which has photon energies of 22 keV ͑85.2%͒, 25 keV ͑16.81%͒, and 88 keV ͑3.61%͒, and a half-life 462.6 days. 16 The 109 Cd calibration standards are purchased with NIST-traceable activity calibrations with an assigned uncertainty of Ϯ5%. These sources are calibrated in terms of activity by intercomparing their 88 keV photon emission rates with NIST's emissionrate standard. Theragenics uses 109 Cd low-to-high energy branching ratios to calibrate their spectrometer with respect to the low-energy photon emission rate. The spectrometer is then used to measure the 20-23 keV photon emission rate from Model 200 seeds representing each batch, which are in turn converted to apparent activity using tabulated photon yields per disintegration. The symbol ''A app,Tnn '' is used to denote the quantity measured by Theragenics' assay, where the ''T'' of the subscript ''Tnn'' denotes Theragenics and ''nn'' denotes the year, e.g., 19nn, that the 109 Cd standard, to which the measurement is traceable, was implemented. As defined by Theragenics, A app,Tnn is the activity of an unencapsulated point source that has the same photon emission rate as the given seed on its transverse axis. For each batch, the apparent activity calibration is transferred to a dose calibrator for assaying the remaining seeds in the batch. Note that A app,Tnn is fundamentally different from apparent activity as defined by the AAPM, 17 A app,N99 , which is a quantity derived from NIST's 1999 standard, S K,N99 .
Theragenics replaces their 109 Cd sources approximately every three years ͑see Table I , column 3͒ in order to maintain an appropriate strength standard for weekly verification of NaI ͑Tl͒ spectrometer sensitivity. Recently, Theragenics analyzed some of its weekly efficiency check data going back to 1988. For each calibration source, the last 6 NaI ͑Tl͒ efficiency measurements ͑count rate/ 109 Cd activity͒ performed were compared to the first six efficiency measurements performed with its replacement. 10 By comparing the average efficiency measured before (nn iϪ1 ) and after (nn i ) replacement of the 109 Cd source implemented in year (nn iϪ1 ), the fractional change in apparent activity values, A app,Tnn iϪ1 /A app,Tnn i , due to calibration source replacement, can be estimated. The corresponding nominal air-kerma strength, S K,Tnn is given by 2, 17 
. Thus, the apparent activity ratio is identical to S K,Tnn iϪ1 /S K,Tnn i ͑see column 5 of Table I͒ . The first calibration source, implemented in year nnϭ1988, covers the 1988-1990 time period during which the Meigooni 3 and Chiu-Tsao 4 dose-rate measurements were performed. These data indicate that Theragenics' assay was essentially constant until fall 1997, when the air-kerma Cd calibration standard used, and time period for the Model 200 source. All numbers have three significant figures ͑generally, one more than is justified͒ to avoid round-off error in the final administered doses.
͑1͒
Row
No. The above analysis depends on the assumptions that ͑a͒ calibration shifts have been caused only by variations in the low-energy photon emission rate per unit stated strength of the 109 Cd standards, and ͑b͒ S K , when independently measured by an appropriate instrument such as the WAFAC, is proportional to NaI ͑Tl͒ count rate. This view is supported by the fact that A app,T97 -to-S K,N99 ratios ͑where S K,N99 represents air-kerma strength as measured by NIST's WAFAC͒ are nearly constant over the range of internal source geometries characteristic of the Model 200 manufacturing history. 8 The uncertainty of the 109 Cd low-energy photon emission rate could be larger than the Ϯ5% uncertainty specified by its vendor because the 20-25 keV photon emission rate per unit activity may vary from source-to-source, relative to the 88 keV emission rate upon which traceability of its activity calibration is based, due to small variations in source geometry. Theragenics' calibration protocol requires 103 Pd seed calibration to be based on the most recently implemented 109 Cd standard without correcting for shifts in spectrometer efficiency relative to either the immediately preceding standard or the one used in 1988. In practice, Theragenics has attributed these observed shifts to actual changes in the NaI ͑Tl͒ spectrometer efficiency, not to differences in the low-energy photon emission rate per unit activity between different calibration sources. Hence the corresponding readjustments in A app,Tnn per unit spectrometer reading were viewed as corrections needed to maintain accuracy of the calibration procedure.
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B. NIST calibration techniques for the Model 200 source
The WAFAC is a cylindrically symmetric free-air chamber with circular electrodes on its proximal and distal faces consisting of very thin aluminized Mylar 5-7 with a collection volume large enough that individual 103 Pd and 125 I seeds can be calibrated. Since 1 January 1999, the WAFAC has been the basis of the U.S. national standard for air-kerma strength. Over the period December 1998 to July 1999, NIST calibrated 12 Model 200 seeds in terms of S K,N99 in preparation for standardizing the Model 200 source in terms of air-kerma strength. 8 The NIST measurements deviated significantly from the vendor's S K,T97 :
Differences of this magnitude are not unexpected, given the influence of the Model 200 source geometry on the 103 Pd spectrum, the poor energy resolution of NaI ͑Tl͒ scintillators, and uncertainty of the low-energy photon emission rate derived from the 109 Cd sources. This discrepancy will not cause patient dose delivery errors, if ⌳ is accurately measured and A app has a constant relation to true S K . By combining Eq. ͑2͒ and column ͑5͒ of Table I , the ratio S K,Tnn /S K,N99 can be derived. Between 1988 and fall 1997, this ratio has remained constant within Ϯ2% of its average value: S K,TϽ97 /S K,N99 ϭ0.836. As noted above, Theragenics has declared its intention to maintain their A app assay at post-1997 levels regardless of which 109 Cd calibration source is used. Thus the ratio S K,T97 /S K,N99 ϭ0.767 will be valid for the foreseeable future. To minimize round-off errors, all intermediate quantities, including the above ratios, carry an additional digit beyond the number justified.
C. Recent dose-rate constant measurements and calculations
The dose-rate constant recommended by TG 43 for the Model 200 source is based upon TLD dose-rate measurements reported by Meigooni 3 and Chiu-Tsao. 4 To estimate the dose-rate constant, ⌳ 95D,T88S , TG 43 took the average of these two reported measurements and applied a multiplicative correction ͑1.048͒ to convert from solid water measurement medium to a liquid water reference phantom:
.
͑3͒
The first subscript, 95D, refers to source of measured dose rate at 1 cm, Ḋ 95D (ϭ/2,rϭ1 cm), which in this case is the TG-43 report published in 1995 ͑The ''D'' stands for ''dosimetry.''͒ The second subscript, terminating in an ''S'' for ''strength,'' refers to the source calibration standard, which in this case is Theragenics' A app assay from the period 1988-1990 ͑T88͒. In preparation for implementing the S K,N99 standard, Theragenics has commissioned two doserate constant determinations. Using TLD dosimeters in a solid water phantom, Nath 13 
D. Constancy of TG-43 dosimetric parameters over Model 200 life span
The Model 200 source has undergone small changes in its internal geometry ͑mostly changes in thickness of the Pd metal coating the graphite pellets͒ resulting from the vendor's transition from lower specific activity reactor-produced 103 Pd ͑hereafter denoted as ''heavy seeds''͒, to higher specific activity accelerator-produced radioactive material ͑''light seeds''͒. To evaluate prescribed-to-administered dose ratios over the Model 200 lifespan, the validity of the ''99D'' dosimetry parameters must be independent of these geometry changes. In addition, any significant differences between the ''99D'' relative dosimetric ratios and the corresponding TG-43 data must be accounted for.
As of this writing, all published descriptions of Model 200 source dose measurements, with the exception of Nath 13 ͑which is limited to the dose-rate constant͒, are based upon the heavy seed design. Recently, Williamson 14 used Monte Carlo simulations to evaluate the sensitivity of the Model 200 parameters to specific activity. His study shows that ⌳ 99D,N99S is nearly independent of the internal geometry variations associated with the transition from heavy to light seeds. In addition, calculated radial dose functions, g(r), for simulated heavy and light seeds are nearly identical, and are in good agreement with the TG-43 data and other ''heavy seed''measurements. 3, 4, 18 The calculated anisotropy functions for heavy and light seeds are also similar, with light seeds exhibiting somewhat smaller ͑2%͒ anisotropy constants, an (r). The calculated heavy-seed F(r,) data are in reasonable agreement with measured data. However, there are no directly measured F(r,) data in the literature for currently produced light seeds. Weaver 19 has used Monte Carlo simulation techniques to infer F(r,) from photon fluence anisotropy profiles measured in air at 1 m from ''light'' seeds. The resultant value of an ϭ0.87 is consistent with Williamson's calculations but about 3% smaller than the 0.90 value recommended by TG 43. However, in the absence of empirically validated Monte Carlo anisotropy calculations, the AAPM does not believe there is sufficient evidence to warrant revision of the TG-43 anisotropy constant at this time. To summarize, for the purposes of reconstructing 103 Pd dose administration history, the AAPM recommends the following approximations:
E. Dose calculation formalisms: Prescribed versus administered dose
The discussion above suggests that the dose received by a patient implanted with Model 200 sources depends both on the source of dosimetry data and the year the sources were calibrated by Theragenics. In this section, an expression is derived that relates dose prescribed based on a given dosimetry dataset and source strength standard to administered dose ͑dose calculated using 99D dosimetry data and calibrations traceable to S K,N99 ). For an arbitrary dosimetry data set, kk, and Theragenics calibration standard, Tnn, the doserate from a single seed using the isotropic point-source formalism 2 is given by
͑5͒
where r 0 ϭ1 cm is the reference distance. The subscript ''Tpp'' denotes the Theragenics calibration standard to which the dose-rate constant is normalized while ''Tnn'' denotes the standard to which the strength of the implanted seeds is traceable. In general Tpp Tnn. Then, the total dose at a point r ជ,D(r ជ) Rx ͑derived from 1999 dosimetry normalized to the 1999 NIST standard͒, is given by averaging the ratio of the doses calculated in the two systems with respect to position r ជ in a typical implant. This yields
where the brackets denote averaging over position. In the general case, the radial dose functions used by the prescription and administration dosimetry systems could differ significantly, requiring numerical evaluation of ͑7͒. However, in our case, combining Eqs. ͑5͒-͑7͒ with Eq. ͑4͒ yields the following simplified expression:
͑8͒
This gives the dose administered to dose prescribed ratio for patients who were treated according to TG-43 dose calculations using seeds with vendor-supplied year nn calibrations, relative to 1999 dosimetry calculations based upon the NIST WAFAC standard. The ratio S K,N99 /S K,Tnn is the ratio of source strengths as measured relative to the indicated standards for same physical seed at the same time.
III. RESULTS AND DISCUSSION
The main results of this communication, the D 99D,N99S
Rx
/D 95D,TnnS
Px ratios as a function of year of treatment, are given in Tables I and II. Column 7 of Table I gives the ratio of administered dose to prescribed dose for the time period covered by each 109 Cd calibration source used by Theragenics. During the period 1988 to September 1997, this ratio ranged from 1.059 to 1.099, averaging 1.075. Columns 6-8 of Table II recapitulate the same data, except that the dose ratio for the 1988-1997 period is replaced by a single average. Columns 7 and 8 of Table II give the administered doses for an assumed prescribed dose of 115 Gy. The AAPM recognizes that although 115 Gy is a widely used dose prescription, other values have been used. To obtain the administered dose corresponding to a different prescribed dose value, the latter should be multiplied by the appropriate ratio in column 7 of Table I or column 6 of Table II. These results show the following:
͑a͒ For implants performed during the period 1988-1997, the administered doses are estimated to be approximately 8% higher than prescribed doses. 109 Cd standard, Theragenics will maintain their calibration assay at post-1997 levels. Thus the administered-to-prescribed dose ratio will remain at 1.17 for the foreseeable future. ͑c͒ For all types of 103 Pd interstitial sources, including the Model 200 seed, treatment plans based on the NIST 1999 standard (S K,N99 ) and appropriately measured or calculated 1999 dosimetry data (⌳ 99D,N99S ) will result in equality of prescribed and administered dose. Hence a prescribed dose of 115 Gy will result in an administered dose of 115 Gy. As of this writing, such data [11] [12] [13] [14] is available for the Mentor PdGold seed. ͑d͒ Finally, if a clinician were to continue using unmodified TG-43 dosimetry parameters (⌳ 95D,T88S ) in conjunction with the 1999 NIST standard, the administered dose would be approximately 10% lower than the prescribed dose, i.e., 115 Gy prescribed would result in an administered dose of 103 Gy.
The data presented here indicate that most of the patients treated with a prescribed dose of 115 Gy received, on average, 124 Gy prior to 1997. This cohort of patients includes all of those followed for more than 5 years and is our best estimate of the monotherapy prostate implant doses actually administered to the patients included in published retrospective reviews assessing clinical outcomes. 21, 22 Therefore, a prescribed dose of 124 Gy best reproduces the evaluated clinical experience based solely on the limited physical issues addressed by this report. However, a large cohort of patients treated between 1997 and the present time have received a larger average dose 135 Gy for the same prescribed dose of 115 Gy. To date, no publications are available to quantify the effects on tumor control and complications, if any, resulting from this larger administered dose. The goal of the AAPM is to provide radiation oncologists and clinical physicists with conversion factors relating prescribed and administered doses for different dosimetry data and calibration standards that will aid in selecting the prescribed dose that best serves their clinical intention.
The dose administered/dose prescribed ratios presented here describe only the systematic effects of modified dosimetry data and source-strength standards. Many other effects, such as dose heterogeneity within individual implants, uncertainties in individual seed calibrations, and patient-to-patient variations in prostate coverage achieved, may affect the relationship between prescribed and administered dose for individual patients. These factors, which vary significantly between patients and brachytherapists, are not considered here. Indeed, one possible clinical interpretation is that the 10%-20% systematic changes in administered dose considered by this report are unimportant in view of the large, apparently random patient-to-patient fluctuations in the administered-toprescribed dose ratio. However, the AAPM emphasizes that the issues addressed by this report are systematic changes that influence all patient treatments in addition to the normal ''random'' uncertainties in treatment delivery.
No rigorous evaluation of the uncertainty in the administered-to-prescribed dose ratios of Tables I and II has been performed. The S K,T97 /S K,N99 ratio was measured by NIST and has an uncertainty of about 1%, while the an and ⌳ 99D,N99S estimates have uncertainties of about 3% and 5%, respectively. The S K,Tnn iϪ1 /S K,Tnn i ratios were based upon a retrospective review of proprietary data by Theragenics personnel and were provided to the Subcommittee without uncertainty estimates. Assuming that the S K,Tnn iϪ1 /S K,Tnn i ratios have uncertainties of about 3%, the administered dose values of Tables I and II have uncertainties on the order of 6%.
IV. CONCLUSIONS AND RECOMMENDATIONS
To implement the recommendations of this report, the following three steps need to be implemented concurrently. Table I 
͑5͒
͑ 6͒ ͑ 7͒ ͑ 8͒ ͑1͒ Row no. ͑1͒ The AAPM recommends that vendor calibrations of 103 Pd interstitial brachytherapy sources be indirectly traceable to NIST's WAFAC-based air-kerma strength standard. Vendor calibration certificates should specify calibrations in terms of air-kerma strength, S K,N99 , directly. ͑2͒ The AAPM recommends that medical physicists should utilize dose-rate constants (⌳ 99D,N99S ) that are normalized to the S K,N99 calibrations, described above, in all treatment planning and evaluation dose calculations. ͑3͒ The AAPM recommends that radiation oncologists ͑with the assistance of medical physicists͒ convert dose specifications and prescriptions based upon older dosimetry systems into the current recommended dosimetry system ͑using ⌳ 99D,N99S ) using the conversion factors given in Tables I and II of this report. This effort requires the radiation oncologist to identify the clinical experience to be duplicated or improved upon.
͑2͒
The system for specifying absorbed dose described by recommendations ͑1͒-͑3͒ should be used for prescribing treatments, documenting treatments in the medical record, and communicating treatment results and protocols to others. Dose prescriptions based upon older dosimetry data and obsolete source-strength standards not meeting these criteria should be translated into these terms using Tables I and II .
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The Subcommittee members would like to thank Dr. Tydings Robin of Theragenics Corporation for the many informative discussions on the basic issues addressed by this report and for analyzing and making available the sourcestrength ratios cited in this report. Answer: With regard to the issues addressed by this report, all seed types are equal. Radiation oncologists using TheraSeed® must recognize that administered doses and prescribed doses have never been equal and that this relationship changed in 1997. They must decide whether to continue using the larger post-1997 administered dose of 135 Gy, reduce the dose to pre-1997 levels, or select an intermediate dose. With other source types, radiation oncologists should review the history of TheraSeed® treatments as given in Table II and make the same decision. Using Table II , any ''old dosimetry'' TheraSeed® treatment can be translated into 1999 dose-specification language. After Theragenics adopts the NIST S K standard early in 2000, dose specification issues will be identical for all seed types.
APPENDIX: EXAMPLES AND FREQUENTLY ASKED QUESTIONS
͑1͒
͑5͒ 103 Pd source models using 1999 dosimetry and S K,N99 ?
Answer: Not without significant modifications. For a given seed spacing and target volume, the Anderson nomograph gives the source strength in mCi needed to deliver a prescribed dose of 115 Gy assuming Model 200 seeds, the A app,T88 calibration and the dosimetry parameters published by Chiu-Tsao which differ slightly from the TG-43 parameters. The nomograph results must be corrected for the choice of prescribed dose relative to 115 Gy and any difference between the 1999 dosimetry parameters appropriate for the seed type you have selected and the S K,N99 standard to which its calibrations are traceable and those of Chiu-Tsao which are based on the Model 200 source and Theragenics' A app,T88 assay method.
Whom to contact for further assistance
If you have questions regarding the recommendations of this report or implementing them in your clinic, please contact the Radiological Physics Center ͑RPC͒ at MD Anderson Cancer Center, Houston, TX at ͑713͒ 792-3226. 
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